(Reuters) -British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for ...

Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...

Gepotidacin was approved by the FDA earlier this year, under the Blujepa brand, as the first oral antibiotic to offer a new ...

It is not clear whether Prasad will still serve as the agency’s chief medical and scientific officer, Stat reports. Meanwhile, Center for Drug Evaluation and Research staff grill top drug regulator ...

GSK plc's experimental antibiotic, gepotidacin, has been granted priority review by the U.S. Food and Drug Administration ...

The global HIV antivirals market is set for a period of robust growth, with a new forecast predicting its value will climb ...

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

Assembly Biosciences is advancing its herpes drug to Phase II trials after it showed 94% antiviral efficacy in a Phase Ib ...

GSK (GSK) stock in focus as the company bid to expand use of oral antibiotic agent gepotidacin for urogenital gonorrhea is granted FDA priority review. Read more here.

The UK's FTSE 100 index showed a modest gain, driven by healthcare and consumer shares. However, concerns over upcoming ...

GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...